Microarray technology GEM microarrays and drug discovery.

Mark A Reynolds

doi:10.1038/sj/jim/7000136

Home/Archive/PubMed

PubMed · 12074093

Microarray technology GEM microarrays and drug discovery.

Mark A Reynolds

View original source ↗Export metadata ↓

Abstract

Incyte Genomics' GEM Gene Expression Microarray is a proven genomics tool used by a large number of pharmaceutical companies to speed up the drug discovery and development process. The development and integration of this technology, together with Incyte's sequence databases and clone resources, have resulted in GEM microarrays that span approximately 60,000 human genes as well as approximately 60,000 plant, rat, mouse, yeast, and bacterial genes. The technology underlying the use of these arrays and their application to the drug discovery process is highlighted.

Explore related subjects

Drug Design Information Management Oligonucleotide Array Sequence Analysis Quality Control Statistics as Topic Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Mark A Reynolds. 2002. Microarray technology GEM microarrays and drug discovery.. https://doi.org/10.1038/sj%2Fjim%2F7000136

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Design and structure-activity relationships of 2-alkyl-3-aminomethyl-6-(3-methoxyphenyl)-7-methyl-8-(2-fluorobenzyl)imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists.

SAR studies of 7-phenylpyrrolo[1,2-a]pyrimid-4-ones 1 and 2, and 2-phenylimidazolo[1,2-a]pyrimidines 3 and 4, as nonpeptide human GnRH receptor antagonists, lead us to believe that the aromatic ring at position-2 of 4 is no longer crucial for the binding once an aryl group is incorporated at postion-6. We report here the use of a 2-alkyl group on the imidazolo[1,2-a]pyrimidone core to generate potent GnRH receptor antagonists. This discovery enabled us to obtain smaller but equally potent GnRH receptor antagonists.

Drug Design↗

PubMed2003

New ligands for defective receptors.

Scientists are trying to create hormone analogues that will work more effectively with defective receptors than natural hormones do.

Drug Design↗

PubMed2003

Recent developments in protein microarray technology.

The sequencing of the human genome and the advent of DNA chips and sophisticated bioinformatics platforms have enabled molecular biologists to take a more global view of biological systems and to analyze naturally occurring genetic variation. Microarrays of antibodies can measure the concentrations of many proteins quickly and simultaneously. Microarrays of genomically encoded proteins allow scientists to screen entire genomes for proteins that interact with particular factors, catalyze particular reactions, or act as substrates for protein-modifying enzymes or as targets of autoimmune responses. The new protein microarray platforms will prove invaluable to basic biological research, and will dramatically accelerate the pace of discovery of drug targets and diagnostic biomarkers.

Drug Design↗